A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation

A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation

Abstract Background CAR T cell therapy is a promising approach to improve outcomes and decrease toxicities for patients with cancer. While extraordinary success has been achieved using CAR T cells to treat patients with CD19-positive malignancies, multiple obstacles have so far limited the benefit o...

Full description

Bibliographic Details
Main Authors: Ha Won Lee, Carla O’Reilly, Alex N. Beckett, Duane G. Currier, Taosheng Chen, Christopher DeRenzo
Format: Article
Language:English
Published: BMC 2024-04-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Ingenol-3-angelate
PKC
B7-H3
CAR
T cell
Osteosarcoma
Online Access:https://doi.org/10.1186/s13046-024-03022-x

Internet

https://doi.org/10.1186/s13046-024-03022-x

Similar Items